SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), a DNA sequencing and
array-based technologies firm, Friday announced that it has signed an agreement
with Janssen Research and Development, LLC to develop its novel molecular
residual disease or MRD assay to detect tumor DNA.

The company said that it intends to deliver an accurate and easily accessible
MRD array with the help of Janssen.

MRD testing is used in oncology to predict disease recurrence.

Currently, Illumina's stock is trading down 1.77 percent, to $128.92 on the
Nasdaq.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX